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ABSTRACT 
  Salmonella enterica is a gastrointestinal (GI) pathogen that can cause systemic 
diseases. It invades the host through the GI tract and can induce powerful immune 
responses in addition to disease. Thus, it is considered as a promising candidate to 
use as oral live vaccine vectors. Scientists have been making great efforts to get a 
properly attenuated Salmonella vaccine strain for a long time, but could not 
achieve a balance between attenuation and immunogenicity. So the regulated 
delayed attenuation/lysis Salmonella vaccine vectors were proposed as a design to 
seek this balance. The research work is progressing steadily, but more 
improvements need to be made. As one of the possible improvements, the cyclic 
adenosine monophosphate (cAMP) -independent cAMP receptor protein (Crp*) is 
expected to protect the Crp-dependent crucial regulator, araC PBAD, in these 
vaccine designs from interference by glucose, which decreases synthesis of cAMP, 
and enhance the colonizing ability by and immunogenicity of the vaccine strains. 
  In this study, the cAMP-independent crp gene mutation, crp-70, with or 
without araC PBAD promoter cassette, was introduced into existing Salmonella 
vaccine strains. Then the plasmid stability, growth rate, resistance to catabolite 
repression, colonizing ability, immunogenicity and protection to challenge of 
these new strains were compared with wild-type crp or araC PBAD crp strains 
using western blots, enzyme-linked immunosorbent assays (ELISA) and animal 
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studies, so as to evaluate the effects of the crp-70 mutation on the vaccine strains.  
  The performances of the crp-70 strains in some aspects were closed to or even 
exceeded the crp+ strains, but generally they did not exhibit the expected 
advantages compared to their wild-type parents. Crp-70 rescued the expression of 
araC PBAD fur from catabolite repression. The strain harboring araC PBAD crp-70 
was severely affected by its slow growth, and its colonizing ability and 
immunogenicity was much weaker than the other strains. The Pcrp crp-70 strain 
showed relatively good ability in colonization and immune stimulation. Both the  
araC PBAD crp-70 and the Pcrp crp-70 strains could provide certain levels of 
protection against the challenge with virulent pneumococci, which were a little 
lower than for the crp+ strains.  
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CHAPTER I 
INTRODUCTION 
PROCEDURE FOR SALMONELLA INFECTION 
  Salmonella enterica is an invasive, facultative intracellular gastrointestinal (GI) 
pathogen (40, 46). Salmonella can infect a broad spectrum of hosts (41, 84), and 
cause multiple diseases such as typhoid fever and gastroenteritis. The infections 
are usually acquired by the ingestion of contaminated food or water (62). In the 
digestive system, activation of virulence factors can help Salmonella survive the 
attacks from gastric acid and other defenses of the host (36), and finally arrive in 
the small intestine, where they will get access to the blood circulation (7, 66).  
  Salmonella preferentially invades and kills the microfold cells (M cell) in the 
epithelium of the Peyer’s patches (48), from where they move to mesenteric 
lymph nodes and continue to circulatory system with the lymph (66), and then are 
quickly cleared by phagocytes in the blood (66). In the Peyer’s patches and lymph 
node, Salmonella interacts and is taken up by dendritic cells (DCs) and 
macrophages (11, 15, 43). Besides, Salmonella has an M cell-independent 
pathway to cross the epithelium, which is completed by CD18+ phagocytes (96). 
After entering the phagocytes, related virulence genes are activated and protect 
the bacteria from being killed. As a result, the pathogen survive in the DCs or  
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phagocytes and spread throughout the reticuloendothelial system (36) with them, 
particularly in liver, spleens and lymph nodes, and replicate there.  
SALMONELLA AS A PROMISING VACCINE VECTOR 
  Several unique characteristics confer Salmonella advantages as a vaccine 
vector.  
  First, Salmonella invades and colonizes in the host immune system, which 
considerably facilitates the antigen exposure and stimulation. They are capable to 
elicit strong innate immunity, cellular responses and high titer of mucosal and 
humoral antibodies (58, 66).   
  Second, this microorganism can establish persistent infection, without inducing 
any notable symptoms. In mouse models, Salmonella can be consistently isolated 
from the spleen, liver, lymph nodes long term after infection, from several months 
up to one year (67, 71, 86), far beyond the regular 3-4 weeks (68). The bacteria 
keep replicating and expressing antigens during their persistence, leading to 
continuous stimulation and long-term immune responses.  
  Third, the instinct of infection through orogastric route makes Salmonella a 
more competent candidate for an oral vaccine, compared with other bacteria 
which infect host via parenteral route. It abrogates needles and thus is more secure, 
convenient and economical than the traditional injected vaccines.  
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  Fourth, some of its components, such as lipopolysaccharide (LPS) and flagellin, 
are considered as adjuvants (8, 18, 81), and can enhance the immunogenicity. 
  In addition, Salmonella is a versatile vector, not only compatible with foreign 
bacterial antigens, but also heterologous antigens from viruses, fungi, parasites, 
and cancer cells (14, 40).  
  Last but not the least, since 1920s, over 30,000 papers (based on Pubmed) 
about this microorganism have been published. The accumulation in relevant 
knowledge and technology enable researchers to engineer the genome according 
human’s expectations.  
LIVE ATTENUATED SALMONELLA VACCINES 
  Attenuation is an important way to generate vaccines. Attenuated vaccines have 
a long history. In the 19th century, the earliest vaccines against fowl cholera and 
anthrax were developed by Louis Pasteur (73). In 1920s, attenuated vaccines 
against tuberculosis, Bacillus Calmette-Guérin (BCG), was obtained after 230 
passages (12). Attenuated Salmonella were first reported in 1951 (1). In 1970s, 
the first attenuated vaccine against human typhoid, Ty21a, was developed through 
chemical mutagenesis (33).  
  With the development of molecular biology, the efficiency to generate 
attenuated strains has been greatly improved, and the previous undirected, 
non-specific and undefined attenuation has been replaced by current directed, 
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specific and defined attenuation. Generally speaking, the attenuation strategy in 
Salmonella can be classified into three groups. 
  Abolishing virulence factors. The virulence factors disabled in these strains 
are mainly related with LPS and Salmonella Pathogenicity Islands (SPIs). The 
Ty21a mentioned above was an instance related to LPS. It contained a mutation in 
galE, which is responsible for biosynthesis of LPS core and O-antigen. Its 
attenuation and immunogenicity has already been demonstrated, but it can only 
provide moderate protection, and its gene background is not clear due to the 
mutagenesis (35). Mutations in other LPS-related genes, including pmi, rfaH, and 
rfc, can achieve partial attenuation and high immunogenicity (19, 24, 55, 56). 
  SPI is a class of genes encoding virulence factors. These clustered genes are 
obtained through horizontal gene transfer from other organisms (62). Some S. 
enterica serovars have up to 14 SPIs (52). Mutations in these pathogenicity 
islands can lead to different levels of attenuation (6, 28, 52, 54, 69, 74, 97). 
Mutants which devoid of the whole SPI-1 or SPI-2 were reported to be able to 
protect chickens from S. Enteritidis challenge and the SPI-1 mutant was more 
effective (63). A vaccine strain harboring mutations in SPI-2 gene ssaV was 
constructed to deliver Chlamydial antigens (91). Deletion of an SPI-5 virulence 
factor, SopB, also proved promotion in immunogenicity and protection of 
Salmonella vaccine vectors (60).   
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  Intervening global regulators. Some proteins in the bacteria are so influential 
that they can regulate the expression of up to hundreds of downstream genes. 
These proteins are called global regulators for their wide influence. Many of them 
are considered to play a crucial role in virulence and their inactivation can result 
in attenuation. crp encodes cAMP receptor protein (Crp) that regulates energy 
metabolism together with its ligand cyclic AMP (cAMP), whose synthesis is 
regulated by cya. In a series of research, various serotypes harboring mutations in 
these two genes proved convincing stability, immunogenicity and avirulence in 
multiple hosts (20, 21, 39, 53, 57, 76, 78, 89, 94, 104). PhoP/PhoQ is a 
two-component system involved in regulation of virulence and resistance to host 
defense (2, 5, 34, 95). ΔphoP (Δ = deletion) impaired bacterial colonization, 
however, the strain still showed high immunogenicity (32). Mutations in rpoS and 
htrA which are associated with stress, as well as mutations in ompR regulating 
other outer membrane proteins all can confer avirulent phenotypes (26, 29, 47). 
Moreover, the attenuation in strains with mutations in fur, which is required for 
iron homeostasis, and inv, which is related to type III secretion system, was also 
reported (93, 98).  
  Blocking metabolism. Bacteria themselves are the only source of certain 
amino acids that cannot be obtained from the host. Attenuated strains arise when 
some of these metabolic pathways are blocked. The first strains were Δaro 
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mutants. aroA, aroC and aroD are involved in synthesis of aromatic amino acids 
and several vitamins. Their roles in virulence and vaccine vectors have already 
been verified by animal studies (10, 16, 42, 49, 65). asd is necessary for 
production of diaminopimelic acid (DAP), which is an indispensible component 
of bacterial cell wall. This gene is also involved in synthesis of threonine, 
methionine and lysine. Δasd strains were over-attenuated and their life time was  
severely impacted, which reduced its immunogenicity (13).  
SALMONELLA VACCINE VECTORS WITH REGULATED DELAYED 
ATTENUATION  
 Attenuation and immunogenicity, in other words, safety and effectivity, are two 
tightly connected aspects of a live vaccine. Appropriate virulence or attenuation 
affords enough invasion and colonization, which is premise for effective immune 
stimulation, and at the same time avoid causing lesions to the host, while 
excessive or insufficient attenuation will lead to low immunogenicity or health 
problems. Balance between them is crucial for a successful live vaccine and also a 
bottleneck for some vaccines, containing Salmonella vaccines. Very few live 
attenuated vaccines reviewed above satisfied the standard of a licensed vaccine, 
although they all showed certain level of immunogenicity or attenuation.  
  Regulated delayed attenuation is a creative strategy to achieve a delicate 
attenuation-virulence balance. The general idea of this design is to maintain a 
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regular expression level of target genes, so as to provide vaccine strains with 
intact invasion and colonization capacity. The target genes will be inactivated 
after entering the host where the inducers necessary for expression of target genes 
are not available, so the strains become attenuated in vivo.   
  This design is realized via a cassette of TT araC PBAD. TT stands for 
transcriptional terminator, which is used to terminate the transcription of the araC 
gene; PBAD is the promoter of the ara operon which is composed of araB, araA 
and araD and is responsible for arabinose metabolism. When the cells are grown 
in LB broth with arabinose, AraC, which is activated by arabinose, together with 
the Crp-cAMP complex will bind to their specific binding sites in the promoter 
region and activate the transcription from PBAD. Consequently, the araC PBAD 
promoted virulence genes can be expressed during growth in the presence of 
arabinose for normal virulence. After entering internal tissues where arabinose is 
unavailable, expression of those virulence genes will gradually cease due to 
dilution of arabinose in the cytosol, which is caused by cell division. Eventually, 
the virulence of the bacteria will be attenuated 
To maximize the colonizing ability and induction of immune responses, and at 
the same time guarantee attenuation, prevent reversion of virulence, and eliminate 
potential side effects, the vaccine strains always integrate more than one genetic 
modification.  
  
8
The promoter of global regulators, such as fur, will be replaced by araC PBAD 
so that the virulence could be regulated by arabinose.  
To coordinate with araC PBAD, araBAD operon, which is responsible for 
arabinose metabolism, is often deleted. This mutation is supposed to enhance 
retention of intracellular arabinose, so as to extend expression of araC 
PBAD-regulated genes. Besides, ΔaraBAD also prevents acid production during in 
vitro growth with arabinose (24). 
Introduction of deletion of LPS-related genes, such as pmi and rfaH, can further 
decrease virulence, as well as enhance exposure of outer membrane antigens to 
increase stimulation of protective immunity (24).  
To avoid safety problems involved in the usage of antibiotics to select for 
expression vectors, a host-vector system called balanced-lethal system is 
introduced to stabilize the plasmid that carries the foreign antigen gene. For 
example, the chromosomal asd is mutated to impose an obligate requirement for 
external DAP, and it will be complemented by a plasmid harboring both asd gene 
and target antigen gene. As a result, the plasmid vector can be stabilized without 
using drug-resistant genes that may lead to safety problems in live vaccines.   
High level expression of foreign antigen genes before administration is a 
burden for the bacteria and may undermine their growth, colonizing ability and 
thus immunogenicity, so araC PBAD lacI and lacI-repressible promoter Ptrc are 
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used to solve this problem. During in vitro growth where arabinose is available, 
LacI is synthesized and repress the Ptrc-promoted antigen gene expression. After 
administration, arabinose is no longer available, thus intracellular arabinose 
concentration gradually reduces with cell divisions, leading to de-repression of 
antigen synthesis. Besides Ptrc and asd, the plasmid usually contains a signal 
sequence belonged to type II secretion system or type III secretion system (50, 77). 
This signal is fused with the antigen sequence to direct the recombinant protein to 
periplasm of the bacterium or the cytoplasm of the host cells to elicit immune 
responses. 
One of pathogen targeted by the regulated attenuated Salmonella vaccine is 
Streptococcus pneumoniae, the major cause of pneumonia (72). One of the 
promising candidates for its vaccines development is pneumococcal surface 
protein A (PspA) (31). PspA is a highly immunogenic surface protein produced by 
all strains of Streptococcus pneumoniae (103). It can induce productive mucosal 
and systemic antibody responses through multiple immunization routes, including 
oral (103), intranasal (64), subcutaneous (87) or intraperitoneal (9) immunization 
of the purified protein, immunization of DNA vaccines (31), the delivery by 
attenuated (70) or regulated attenuated (50, 80, 101, 102) Salmonella vectors, or 
other bacterial vectors (30). Its capacity in eliciting cellular immunity was also 
proved (3).   
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  Several series of regulated attenuated vaccine strains of S. Typhi or S. 
Typhimurium have been designed and constructed following the principles above. 
They demonstrated the expected phenotypes and also exhibited promising results 
of attenuation, colonizing ability, immunogenicity and protection (23, 56, 59, 79). 
However, the feedbacks from clinical trials indicate the regulated attenuated 
Salmonella vaccines still need more improvement.  
PROBLEM AND HYPOTHESIS 
  It seems that current regulated delayed attenuation strains still need to be 
engineered to achieve the balance between attenuation and immunogenicity, and 
one of the exposed issues points at the weakened colonizing ability of those 
strains. The actual situation in the GI tract is far more complex than anyone 
imagined, and the realization of the design is not only threatened by host defense, 
but also intervened by various digesta, such as glucose and other sugars. 
Moreover, glucose is the best carbon source for Salmonella, and always included 
in the broth for better growth. Hence, the central regulator in these bacteria, araC 
PBAD, is almost inevitably be inactivated by the presence of glucose or other better 
carbon sources, not being able to achieve the optimal regulatory effects.  
Catabolite repression. Smaller molecules produced during the process of 
release of energy and breakdown of larger molecules are called catabolites. When 
bacteria grow in the presence of several different carbon sources, they 
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preferentially use the best one that yields the most energy, while repressing 
transcription of operons involved in utilization of other carbon sources. This 
mechanism is called catabolite repression. The genes subject to catabolite 
repression, known as catabolite-sensitive genes, will be activated when the poorer 
carbon source is the only available one. For Salmonella, glucose is a better carbon 
source than any other one including arabinose, so araC PBAD regulated genes will 
be repressed until glucose is depleted (82).  
Catabolite regulation mechanism. As mentioned above, Crp is a global 
regulatory protein and involved in activation of transcription of more than 150 
catabolite-sensitive genes (100), and it plays a significant role in activating 
expression of araC PBAD regulated genes. The binding of its ligand, cAMP, 
changes the conformation of Crp, helps it to recognize the specific binding site 
and enhances its interaction with DNA and with RNA polymerase (37). From this 
perspective, the Crp-cAMP complex, rather than Crp, and the series of events 
afterwards, are required for the transcription activation of catabolite sensitive 
genes. When good carbon sources like glucose are present, cAMP synthesis is 
impacted and cAMP level becomes low, catabolite-sensitive operon expression is 
consequently repressed. In contrast, if the cells grow in poor carbon sources like 
arabinose, both cAMP level and related catabolite-sensitive operon expression 
level will be high (82).  
  
12
cAMP-independent Crp. During studies in Crp structure, scientists discovered 
some amino acid substitutions in Crp would generate a type of allosteric proteins 
later known as Crp*. Crp* has a similar conformation to that of Crp-cAMP 
complex, which provides it the capacity to activate Crp-regulated genes without 
help of cAMP (37, 99), and thus to do so in the presence of glucose.  
The interesting properties of Crp* brought some inspiration to solve the 
problem raised by catabolite repression. Several S. Typhimurium strains harboring 
mutated crp genes for different Crp* were constructed and tested in our lab, and 
the strain with the strongest Crp* phenotype was selected for further study. The 
selected Crp* named Crp-70 contains three amino acid substitutions: T127I, 
Q170K and L195R. Crp-70 was expected to provide a shield against catabolite 
repression to araC PBAD regulation. My project was to introduce the crp-70 into 
the genome of recombinant attenuated Salmonella vaccine χ11443 and investigate 
the effects of this mutated Crp in the vaccine strains.  
CHAPTER II 
MATERIALS AND METHODS 
  Bacterial strains, plasmids, media, and growth conditions. The bacterial 
strains and plasmids used in this study are summarized in Table 1. Escherichia 
coli and S. enterica serovar Typhimurium cultures were grown at 37°C in LB 
broth or on LB agar containing 0.1% glucose (4). When needed, corresponding 
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sugars and/or antibiotics were added to the media at the following concentrations: 
arabinose, 0.05% or 0.2%; mannose, 0.1%; glucose, 0.1% or 0.4%;  
TABLE 1. Strains and plasmids used in this study 
a
 Kmr, kanamycin resistance; Cmr, chloramphenicol resistance 
 
Strain or plasmid Relevant characteristicsa Source or reference 
Strains     
  E. coli     
    χ7213 thi-1 thr-1 leuB6 fhuA21 lacY1 glnV44 
ΔasdA4 recA1 RP4 2-Tc::Mu [λpir]; 
Kmr 
(76) 
  S. Typhimurium     
    χ3761 Wild-type UK-1 (25) 
    χ8093 χ3761 Δcrp-27 Lab stock 
    χ9021 χ3761 ΔPcrp527::TT araC PBAD crp (23) 
    χ11443 ΔasdA33 ΔrelA198::araC PBAD lacI 
TT ΔaraBAD23 ΔPfur81::TT araC PBAD 
fur Δpmi-2426 
Karen 
Brenneman 
    χ11464 χ11443 ΔPcrp527::TT araC PBAD crp Karen 
Brenneman 
    χ11541 χ11443 ΔPcrp70::TT araC PBAD crp-70 This study 
    χ11550 χ11443 crp-70 This study 
    χ11695 χ3761 ΔPcrp70::TT araC PBAD crp-70 This study 
    χ11700 χ3761 crp-70 This study 
  S. pneumoniae     
    WU2 Encapsulated type 3 (9) 
Plasmids     
  pYA3493 Asd+, bla-SS-based periplasmic 
secretion plasmid pBRori 
(50) 
  pYA4088 0.8-kb DNA encoding the α-helical 
region of PspA (Rx1 [aa 3-285]) in 
pYA3493 
(102) 
  pYA4764 sacB mobRP4 oriR6K Cmr ΔPcrp70::TT 
araC PBAD crp-70 
Maria Dolores 
Juarez-Rodriguez 
  pYA5051 sacB mobRP4 oriR6K Cmr Pcrp Chang-Ho Baek 
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chloramphenicol, 20 μg/ml. 5% sucrose was added to LB agar for sacB gene 
based counter-selection for allele exchange experiments (51). 50 μg/ml DAP was 
added for the growth of Δasd strains (22). Streptococcus pneumoniae WU2 was 
maintained at -80°C and was cultured in blood agar in an anaerobic container at 
37°C. Lethal dose 50% (LD50) of the WU2 strain was 500 colony-forming units 
(CFUs), and the concentration of this strain stock was 8.9 × 106 CFUs/ml. 
MacConkey agar with 1% lactose was used to differentiate Salmonella and E. coli 
in Peyer’s patches. 
  Construction of Salmonella strains. The parent strain and χ7213 harboring a 
suicide vector were mixed at ratio of 1:1.2. The mixture was plated on LB agar 
with 100 μl Colicin B (100-fold dilution of supernatant of E. coli culture) and 20 
μg/ml chloramphenicol. Single colonies were picked and cultured in LB broth to 
optical density at 600 nm (OD600) 0.1-0.2. Broth with bacteria was diluted 10 and 
100 folds and spread on LB agar with 5% sucrose (51). Primers crp-up-KpnI 
(5’-cgaggtaccagggctcgttcatttctcac-3’, 527 bp upstream of crp) and crp-R0 
(5’-acgagagagaaaagcaag-3’, 129 bp downstream of crp) will generate a 3-kb 
polymerase chain reaction (PCR) fragment for ΔPcrp70::TT araC PBAD crp70 and 
ΔPcrp527::TT araC PBAD crp, while a 1.3-kb PCR fragment for  crp-70 and crp+. 
The PCR products were purified and sent to sequence to confirm the three 
mutations. Other gene mutations in the strains were also confirmed through PCR. 
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Suicide vector pYA4764 derived from pRE112 was used to introduce ΔPcrp70::TT 
araC PBAD crp-70 into χ3761 and χ11443 to generate single-mutation strain 
χ11695 and vaccine strain χ11541; while suicide vector pYA5051 which was also 
derived from pRE112 was used to introduce Pcrp into χ11695 and χ11541 to 
substitute ΔPcrp70::TT araC PBAD, producing single-mutation strain χ11700 and 
vaccine strain χ11550.  
  LPS analysis. Cells was grown overnight in nutrient broth at 37°C with 
aeration, with 0.2% arabinose, 0.4% glucose, with or without 0.1% mannose. 1 ml 
cell culture was pelleted and resuspended using Dissociation Buffer I (0.5 M 
Tris-OH pH 6.8, 10% glycerol, 10% SDS, 0.05% bromophenol blue, 10% 
β-mercaptoethanol), boiled for 10 minutes, and then diluted with Dissociation 
Buffer II (Dissociation Buffer I without β-mercaptoethanol). Proteins were 
digested by Proteinase K (20 mg/ml). Then the samples were separated on a 12% 
SDS-PAGE gel. The gel was fixed by fixative solution (40% ethanol and 5% 
acetic acid), and then washed with periodic acid solution (1.2 g periodic acid in 
200 ml fixative solution) and stained by silver nitrate mix (dH2O 150 ml, 1M 
NaOH 2.9 ml, ammonium hydroxide 2 ml, and 1g silver nitrate in 5 ml dH2O). 
The gel was washed and developed with developer solution (citric acid 0.025 g 
and formaldehyde 0.25 ml in 500 ml dH2O) until LPS bands were visible, and 
then the reaction was stopped by stop solution (1% acetic acid in dH2O). 
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Growth curve determination. Strains were statically cultured in LB broth 
with 0.05% arabinose at 37 °C overnight. The bacteria were inoculated into fresh 
LB broth with 0.2% arabinose at ratio of 1:50, with or without 0.4% glucose, and 
cultured at 37 °C with aeration for six hours. The OD600 was measured and 
recorded every 20 minutes. At last the data were put into a coordinate system to 
generate the growth curve.  
Plasmid stability. Vaccine strains with pYA4088 or pYA3493 were grown in 
LB broth at 37°C on a shaker at 100 rounds per minute, with 0.2% arabinose and 
50 μg/ml DAP. Every 12 hours 100 μl culture was diluted to 1000 CFUs/ml and 
the rest was inoculated into fresh media, at a ratio of 1:100, for subculture. 200 μl 
of diluted culture (containing around 200 CFUs) was plated onto LB agar with 
0.2% arabinose and 50 μg/ml DAP, and 100 colonies appeared on the agar were 
patched onto LB agar containing 0.2% arabinose with 50 μg/ml DAP and the LB 
agar only containing 0.2% arabinose, respectively. The agar was incubated at 
37°C overnight. The ratio of (colony number on arabinose+ LB/ colony number on 
arabinose+ DAP+ LB) represented the stability of the plasmid in the strains. 
Repeat this procedure for 5 times, and at the last time, the LB broth culture was 
inoculated into LB broth with 0.2% arabinose, 0.4% glucose and 0.1% mannose at 
a ratio of 1:50, to test the expression of the antigen encoding sequence in the 
plasmid.  
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SDS-PAGE and western blot analysis. Strains were grown in LB broth at 
37°C with aeration, with 0.2% arabinose and 0.1% mannose, with or without 0.4% 
glucose, until OD600 reached 0.9. When testing the expression of antigen gene 
from Ptrc in the plasmid, 1mM isopropyl-β-D-thio-galactoside (IPTG) was added 
after OD600 reached 0.9 and continued the culture for 3 hours. Then the bacteria 
were harvested, pelleted, boiled and normalized with loading buffer. Proteins were 
loaded to 12% SDS PAGE gels and the loading volume of each protein was 
determined by its signal intensity. The samples were separated through 
electrophoresis and then transferred to nitrocellulose membranes. The membranes 
were blocked in 5% skim milk in phosphate-buffered saline (PBS) with 0.05% 
Tween 20 (pH 7.4) overnight. After incubation with corresponding antibody from 
rabbit and an alkaline phosphatase-conjugated goat anti-rabbit IgG 
(Sigma-Aldrich, St. Louis, Missouri), the membranes were developed with BCIP 
(5-bromo-4-chloro-3-indolylphosphaten)-NBT (nitroblue-tetrazolium) (Sigma 
-Aldrich, St. Louis, MO). The dilutions of anti-sera against PspA, Crp, Fur, LacI, 
GroEL, and rabbit IgG were 1:10000, 1:2500, 1:4000, 1:10000, 1:10000, and 
1:10000 respectively. When the signals were visible, the reaction was stopped by 
washing with water.  
  Mice. 6-week-old female BALB/c mice were ordered from the Charles River 
Laboratories. All animal studies were approved by the Arizona State University 
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Institutional Animal Care and Use Committees. After arrival, the animal 
experiment would not start until the mice were acclimated and quarantine for 
seven days.  
  Immunization. Strains were statically cultured in LB broth with 0.05% 
arabinose at 37 °C overnight. The bacteria were inoculated into fresh LB broth at a 
ratio of 1:50, with 0.2% arabinose, 0.4% glucose and 0.1% mannose (mannose 
was not included in the broth for single-mutation strains), and cultured at 37 °C 
with aeration until the OD600 reached 0.9. Cells were harvested, pelleted and 
resuspended with 1/100 volume of buffered saline with gelatin (BSG), which 
means the cells were concentrated to around 5 × 1010 CFUs/ml. 100 μl of the cell 
suspension was serially diluted to 5 × 102 CFUs/ml and then plated on LB agar 
with 0.05% arabinose to determine actual titers. Each mouse was orally 20 μl 
suspension of vaccine strains (1 × 109 CFUs), control strains (1 × 109 CFUs) or 
BSG. 
  Colonization assay. On Days 3 and 6 post immunization, 3 mice in each group 
were euthanized. The Peyer’s patches, spleens and livers were extracted, weighed, 
homogenized and plated on LB agar (spleen and liver) with 0.05% arabinose or 
MacConkey agar (Peyer’s patch) with 1% lactose and 0.05% arabinose. For 
bacteria grown on the MacConkey agar, Δpmi was amplified to determine if they  
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were the Salmonella vaccine strains. At last, the number of CFU on the agar was 
recorded with regard to the organ’s weight.   
  Enzyme-linked immunosorbent assay (ELISA). Sera and vaginal secretions 
were collected at Weeks 2, 4, 6, and 8 after immunization. ELISA was used to 
detect the titers of anti-PspA IgA, anti-PspA IgG and anti-LPS IgG in these 
samples. Purified PspA-Rx1 or LPS (Sigma-Aldrich, St. Louis, MO) was coated 
on 96-well Nunc-Immuno MaxiSop plates (Nalgene Nunc International, 
Denmark), 100 ng/well. Blocking was completed with a PBS (pH7.4) solution 
containing 10% Sea Blocking Buffer (Pierce, Rockford, IL). For anti-PspA IgG 
reaction, the starting dilution of serum obtained at the 2nd, 4th, 6th and 8th week 
was 1:200, 1:400, 1:600 and 1:800 respectively, while that for anti-LPS IgG was 
1:400, 1:600, 1:800 and 1:1000. The vaginal secretion was diluted 1:10, 
regardless of collecting time. Then those diluted samples were serially double 
diluted from the top to the bottom of the plate, 100 μl/well. In each plate, each 
column represented one mouse. After incubation in 4°C overnight, plates were 
treated with a biotinylated goat anti-mouse IgG or IgA (SouthernBiotech, 
Birmingham, AL, 1:10000) and a streptavidin-alkaline phosphatase conjugate 
(SouthernBiotech, Birmingham, AL, 1:4000), 1 hour in 37 °C for each. Substrate 
para-Nitrophenylphosphate (pNPP) (Sigma-Aldrich, St. Louis, MO) was 
dissolved in glycine buffer (7.51 g glycine, 203 mg MgCl2 and 136 mg ZnCl2 in 1 
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L H2O, pH 10.4), 1 tablet for each 10 ml of buffer. 100 μl substrate buffer was 
added into each well, and then the plates were put into dark environment in 37 °C 
for 20 minutes. 50 μl 3M NaOH solution was added to stop the reaction. The 
absorbance at 405 nm of each well was recorded by an automatic ELISA reading 
machine. Wells with absorbance higher than 0.1 were considered positive.  
  Pneumococcal Challenge. At week 10 after immunization, the S. pneumoniae 
WU2 stock in -80 °C was thawed and diluted to 2.5 × 105 CFUs/ml. 100 μl was 
taken out and diluted to 2.5 × 102 CFUs/ml, plated on blood agar and grown in an 
anaerobic container at 37 °C overnight, in order to determine the actual titer. Each 
mouse was challenged with 100 μl diluted S. pneumoniae WU2, which contained 
50-fold LD50 or 25,000 CFUs, through intraperitoneal injection.  
  Statistic analysis. All data analysis was conducted by GraphPad Prism 5.0 
(GraphPad Software, San Diego, CA). Two-way ANOVA and Bonferroni’s test 
were used to analyze multiple comparisons among groups. If P<0.05, the 
difference was considered significant. The results were expressed as means ± 
standard errors. 
CHAPTER III 
RESULTS 
Strains with crp mutations are constructed. The strains used in this study, 
χ11443, χ11464, χ3761, χ9021 and χ8093, were obtained from the strain stock of 
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our lab (Table 1). New strains harboring mutations ΔPcrp70::TT araC PBAD crp-70 
and crp-70 were constructed via allele exchange (51), using suicide vectors 
pYA4764 and pYA5051 which were derived from pRE112. First, TT araC PBAD  
 
FIG. 1. Verification of genotypes by colony PCR. 3-4 colonies were picked for 
colony PCR. The length of PCR products of ΔPcrp70::TT araC PBAD crp-70 was 3 
kb, and that of crp-70 was 1.3 kb. P: positive control. N: negative control. M: 
marker. Lanes with only numbers but not any other marks were PCR products 
from colonies after the first allele exchange. (A) Agarose gel electrophoresis 
image of χ11541 (araC PBAD crp-70). (B) Electrophoresis image of χ11550 
(crp-70). (C) Electrophoresis image of χ11695 (araC PBAD crp-70). (D) 
Electrophoresis image of χ11700 (crp-70).   
  
22
crp-70 in pYA4764 was used to replace the crp gene in vaccine strain χ11443 and 
wild-type strain χ3761, generating new strains χ11541 and χ11695, respectively. 
Then the promoter of crp in the two new strains was changed to Pcrp which was 
the wild-type crp promoter using pYA5051, generating χ11550 and χ11700. The 
mutations of crp, as well as other mutations, were confirmed by PCR (Fig. 1). The 
three mutations conferring the Crp* phenotype were verified through sequencing.  
pYA4088, the vector expressing pneumococcal surface protein A (PspA) 
originating from S. pneumoniae Rx1, was introduced into vaccine strains χ11443, 
χ11464, χ11541, and χ11550, through electroporation. pYA3493, the vector 
without the pspA sequence, was introduced into χ11443 and the resulted strain 
served as a vector control in the animal experiment.  
  Vectors were stable in the vaccine strains. After the vectors, pYA4088 or 
pYA3493, were introduced into the vaccine strains, the stability of these vectors 
was tested. As indicated by Table 2, the vectors stayed stable in the strains and the 
asd gene in the vector still complemented the asd mutation in the genome after  
TABLE 2. Plasmid stability in vaccine strains 
Strains 
(vector) 
χ11443 
(pYA4088) 
χ11464 
(pYA4088)
χ11541 
(pYA4088)
χ11550 
(pYA4088)
χ11443 
(pYA3493) 
Stabilitya 99.8% 100% 100% 100% 100% 
  a Stability was calculated by (sum of the colonies on arabinose+ agar of the five 
times)/(sum of the colonies on arabinose+ DAP+ agar of the five times) × 100%. 
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60-hour continuous growth without selective pressure, which resulted in survival 
without external DAP.  
   
FIG. 2. Confirmation of PspA synthesis by western blot after 60-hour 
consecutive culture. The strains from the last subculture in stability test were 
grown in LB broth with aeration with arabinose, mannose and glucose. The 
antigen gene expression was induced for 3 hours by 1mM IPTG after OD600 
reached 0.9. The protein was probed by rabbit polyclonal anti-PspA serum. The 
product of housekeeping gene groEL was used as a normalization control.  
 
The antigen synthesis after the continuous culture was also confirmed. The 
antigen gene expression in the last subculture was induced by 1 mM IPTG and the 
PspA in the cell lysate was analyzed by western blot (Fig. 2). χ11443(pYA4088), 
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χ11464(pYA4088), χ11541(pYA4088), and χ11550(pYA4088) all showed PspA 
synthesis while χ11443(pYA3493) did not, indicating the antigen encoding 
sequence in the vector was as also stable after consecutive replications.  
LPS and antigen can be synthesized in the vaccine strains. Due to the Δpmi 
mutation, LPS synthesis would be impacted without external mannose, which 
would reduce invading and colonizing ability. So the vaccine strains prepared for  
 
FIG. 3. LPS synthesis of the vaccine strains. The LPS samples were prepared 
from cells which were grown in nutrient broth with 0.2% arabinose and 0.4% 
glucose, with or without 0.1% mannose, with aeration overnight at 37 °C, and 
analyzed by SDS-PAGE gel.  
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vaccination were grown with 0.1% mannose, as well as 0.2% arabinose and 0.4% 
glucose . It was expected LPS would be synthesized with external mannose before 
administration, while the synthesis would cease in vivo without available 
mannose. Therefore LPS synthesis was detected with and without mannose. As 
evidence by Fig. 3, when external mannose was not available, all but wild-type 
strain χ3761 could not synthesis LPS properly; while if the external mannose was  
 
FIG. 4. Confirmation of PspA synthesis by western blot. The strains were 
grown in LB broth with aeration with 0.2% arabinose and 0.1% mannose, with or 
without 0.4% glucose. The antigen gene expression was induced for 3 hours by 
1mM IPTG after OD600 reached 0.9. The protein was probed by rabbit polyclonal 
anti-PspA serum. The product of housekeeping gene groEL was used as a 
normalization control.  
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added, the LPS levels of the vaccine strains were similar to that of χ3761. This 
distinction reflected the Δpmi exerted its expected function.  
The synthesis of the foreign antigen PspA, was also confirmed. The antigen 
gene expression, with or without glucose, was induced by 1mM IPTG for 3 hours. 
Cell lysate was normalized and analyzed by western blot (Fig. 4). Rabbit 
anti-PspA polyclonal serum detected a protein band of 37 kDa produced by strains 
carrying pYA4088, while could not detect any signals in strains with pYA3493, 
thus the antigen gene expression was proved. The antigen synthesis levels were 
similar regardless of the existence of glucose.   
Strains with wild-type Crp grows faster than Crp-70 strains. Growth curves 
were drawn to determine the mutations’ effects on growth. The single-mutation 
strains were grown in 0.2% arabinose with or without 0.4% glucose. The Fig. 5A 
and B indicated the Crp+ strains χ3761 and χ9021 grew faster than the Crp-70 
strains χ11695 and χ11700, regardless of the presence of glucose, and the former 
reached higher levels at the stationary phase. On the other hand, because of Δpmi 
mutation, the vaccine strains were grown in 0.2% arabinose, with or without 0.1% 
mannose and 0.4% glucose (Fig. 6A and B). The Crp+ strains χ11443(pYA4088) 
and χ11464(pYA4088) and empty vector strain χ11443(pYA3493) showed some 
advantages in growth, and the growth rate of the araC PBAD crp-70 strain  
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χ11541(pYA4088) was the lowest among the four, with a lag of 1-2 hours to reach 
maximum levels.  
 
 
FIG. 5. Growth curves of the single-mutation strains. OD600 was measured 
every 20 minutes. These strains were cultured in LB broth with 0.2% arabinose, 
with (B) or without (A) 0.4% glucose.  
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FIG. 6. Growth curves of the vaccine strains. OD600 was measured every 20 
minutes. The vaccine strains were cultured in LB broth with 0.2% arabinose (A), 
or 0.2% arabinose, 0.4% glucose and 0.1% mannose (B). 
 
Crp-70 saves araC PBAD-regulated fur expression in the presence of glucose. 
The resistance of Crp-70 to glucose repression was demonstrated through the  
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FIG. 7. Crp-70’s effect on araC PBAD-regulated fur and lacI. Two colonies from 
each vaccine strain were cultured in LB broth with 0.2% arabinose, 0.1% 
mannose, with (Lane 2) or without (Lane 1) 0.4% glucose. The cell lysate was 
separated on a 12% SDS-PAGE gel. GroEL served as control. The loading 
volume for Crp, Fur, LacI and GroEL were 15μl, 15μl, 5μl and 3μl. The proteins 
were probed respectively by rabbit antiserum against Crp, Fur, LacI and GroEL.  
 
expression of araC PBAD-promoted fur and lacI within the vaccine strains. The 
cells were cultured in LB broth with 0.2% arabinose and 0.4% glucose. To 
simulate the condition used for cells prepared for vaccination, 0.1% mannose was 
also included. The housekeeping gene groEL was used as a control of 
normalization. Comparison between χ11541(pYA4088) and χ11464(pYA4088) 
showed Crp-70 partially saved araC PBAD crp-70 expression when glucose was 
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present (Fig. 7). Wild-type crp expression was repressed by glucose in 
χ11443(pYA4088), while that of crp-70 in χ11550(pYA4088) was very low. In 
χ11541(pYA4088) and χ11550(pYA4088), Crp-70 apparently overcame the 
catabolite repression on fur and fur expression levels were quite similar, whereas 
fur expression was repressed in χ11443(pYA4088) and χ11464(pYA4088) grown 
in broth with glucose. In χ11541(pYA4088) and χ11550(pYA4088), Crp-70 
partially recovered the expression of araC PBAD lacI, compared with the Crp+ 
strains, but the recovery was not as obvious as that of fur. When growing with 
0.2% arabinose, 0.4% glucose and 0.1% mannose, the Crp-70 effect on fur was 
evident, thus this condition was decided as the one to prepare vaccine strains for 
immunization. 
Strains with Pcrp colonize better. Single-mutation strains were cultured in LB 
broth with 0.2% arabinose and 0.4% glucose to 5 × 108 cells/ml, and each mouse 
was orally inoculated with 1 × 109 cells. Colonization in spleen, Peyer’s patches 
and liver were determined on days 3 and 6 post immunization. In the Peyer’s 
patches (Fig. 8B and E), which were the main start point of the Salmonella 
invasion, colonization was stable among all the strains. The colonies detected in 
this organ concentrated in 104-106 CFUs per gram of organ samples, and there 
were not any significant differences (P>0.05). The profiles of colonization in 
spleen and liver were roughly the same (Fig. 8A, C, D and F). On both day 3 and  
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FIG. 8. Colonization of single-mutation strains. BALB/c mice were orally 
immunized with 1 × 109 CFUs of the χ3761 (crp), χ9021 (araC PBAD crp), χ11695 
(araC PBAD crp-70), χ11700 (crp-70), and χ8093 (Δcrp). Mice were euthanized on 
days 3 and 6 after immunization. The data represent colonization in spleen (A and 
D), Peyer’s patches (B and E) and liver (C and F) on days 3 and 6, indicating the 
mean of log10 (CFUs/g) ± standard error (SE) per mouse.  
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6, χ3761 (wild-type crp) and χ11700 (crp-70) colonized significantly better than 
others in both organs (P<0.05). On day 3, the colonizing ability of χ9021 (araC 
PBAD crp) was closest to the Pcrp strains χ3761 and χ11700. The colonization of 
χ11695 (araC PBAD crp-70) was the lowest, even lower than χ8093 in which the 
crp was deleted, but the difference between these two strains was not significant. 
On day 6, the colonization of χ11695 increased and was almost equal to that of 
χ9021, while χ8093 became the lowest strain, but there were no significant 
differences.  
The procedure to determine colonization of the vaccine strains was generally 
the same, except that 0.1% mannose was also included in the broth for Δpmi. 
Unlike the single-mutation strains, the colonization numbers were unusually low 
and variable. Very rare colonies could be detected in most samples, indicating the 
colonizing ability of the vaccine strains was heavily impaired, or that cells were 
capable of colonizing but their colony formation in vitro were unaffected.  
χ11443(pYA4088), χ11464(pYA4088) and χ11550(pYA4088) induce strong 
IgG responses. Sera and vaginal secretion were collected from mice at the 2nd, 
4th, 6th and 8th week after oral immunization with 1 × 109 CFUs (actually 1.8 × 
109 CFUs) of vaccine strains. The levels of antibodies, specifically, anti-PspA IgA, 
anti-PspA IgG and anti-LPS IgG, were titered with ELISA. Vaginal secretion was 
used for IgA detection. The results reflected that the vaccine strains did not induce  
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FIG. 9. Antibody responses to PspA and LPS. BALB/c mice were orally 
immunized with 1 × 109 CFUs of vaccine strains χ11443(pYA4088), 
χ11464(pYA4088), χ11541(pYA4088), χ11550(pYA4088), χ11443(pYA3493) and 
20 μl of BSG respectively. Serum and vaginal fluid were collected at weeks 2, 4, 
6 and 8 post immunization. The data showed the average log10 (anti-PspA IgG 
titer) ± standard error (SE) (A), log10 (anti-LPS IgG titer) ± SE (B), and log10 
(anti-PspA IgA titer) ± SE (C) in each mouse at the time point.  
 
 
  
34
good IgA responses (Fig. 9C). The IgA titer of most groups was lower than 1:10. 
χ11464(pYA4088) induced the highest anti-PspA IgA among the six groups. 
χ11443(pYA4088), χ11464(pYA4088), χ11550(pYA4088) and the empty vector 
control χ11443(pYA3493) elicited similar anti-LPS antibodies in a high level, 
which was around 100 times higher than what was elicited by χ11541(pYA4088) 
at all time points except Week 2 (Fig. 9B). In terms of anti-PspA IgG, mice 
immunized with χ11443(pYA4088), χ11464(pYA4088) and χ11550(pYA4088) all 
developed significantly higher titers than χ11541(pYA4088) during Week 4 to 
Week 8, and alike the anti-LPS IgG, the differences between the anti-PspA titers 
of χ11541(pYA4088) and other vaccine strains were also over 100 times (Fig. 
9A).  
  χ11464(pYA4088) protects the animals from pneumococcal challenge. After 
10 weeks of immunization, the mice were challenged i.p. with 25,000 CFUs (50 
LD50) of S. pneumoniae WU2. Most deaths occurred within 4 days after challenge 
(Fig. 10). All vaccine strains showed certain level of protection: 23% of the mice 
vaccinated with χ11541(pYA4088) and χ11550(pYA4088), and 35% vaccinated 
with χ11443(pYA4088) survived the challenge. While χ11464(pYA4088) had the 
highest efficacy (41%) among the four and it was the only one providing 
significantly higher protection when compared with the BSG and empty vector 
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FIG. 10. Survival to pneumococcal challenge. BALB/c mice were orally 
immunized with 1 × 109 CFUs of vaccine strains χ11443(pYA4088), 
χ11464(pYA4088), χ11541(pYA4088), χ11550(pYA4088), χ11443(pYA3493) and 
20 μl of BSG respectively. At week 10 after immunization, mice were challenged 
with 50 LD50 S. pneumoniae WU2 (25,000 CFUs) i.p. Mortality was monitored 
for 2 weeks and no change occurred after 9 days. The numbers in the end of each 
legend represent surviving mice/total mice.  
 
groups. The protection by χ11443(pYA4088) and χ11541(pYA4088) was 
significantly higher than the empty vector strain.  
CHAPTER IV 
DISCUSSION 
  Crp is an important global regulator involved in metabolism, and also plays a 
crucial role in the regulation of regulated delayed attenuation system. It was 
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expected the modification in its structure (Crp*) might lead to effective arabinose 
regulation in the presence of glucose, and thus improve the invading and 
colonizing ability of the regulated delayed attenuated Salmonella vaccine strains. 
Based on this hypothesis, I constructed several vaccine strains harboring one of 
the Crp*s, Crp-70, verified their genotypes and phenotypes, and compared their 
resistance to catabolite repression, colonizing capacity, immunogenicity and 
protection with corresponding Crp+ vaccine strains.  
  Transcription activation independent of cAMP or catabolite repression is the 
most important property of Crp*. My data confirmed that Crp-70 could overcome 
the catabolite repression on araC PBAD promoted genes, but there is still 
something interesting in Fig. 7. First, obviously, the Crp-70 effect on lacI and fur 
was not the same although they used the same promoter. As we know, the 
interaction between one gene product and another gene is not only decided by 
specific binding, but also influenced by the distance and spatial arrangement 
between the genes (88). The different distances or the relative positions between 
crp and fur and that between crp and lacI might affect the cAMP-independent 
activation of Crp-70. It was also possible that the Crp-70 effect is only visible 
when the regulated gene expression is low, or it can only restore the regulated 
gene expression to a relatively low level. In Fig. 7, we did see the araC PBAD fur 
and araC PBAD lacI in χ11541 and χ11550 were recovered to similar low levels 
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when glucose was present. However, more accurate quantitative detection 
methods are required to test this hypothesis.  
Second, in both χ11443 and χ11550, the Pcrp crp+/crp-70 expression was 
reduced when glucose was present. According to the discovery by Hitoshi 
Ishizuka (44, 45), glucose not only reduces intracellular cAMP level, but also 
lowers Crp level by down-regulating its gene transcription initiation. This theory 
explains the repression on the Pcrp promoted crp/crp-70 in χ11443 and χ11550. 
Third, in χ11541 and χ11550, similar levels of Fur were synthesized in the cells 
with different amount of Crp-70. This phenomenon may indicate that the 
interaction between fur and Crp-70 did not require high amount of Crp-70 to 
achieve the largest efficiency in Fur synthesis.  
  Strains with single mutations, even χ8093 in which crp is deleted, all revealed 
decent colonizing capacity. However the colonization results of the vaccine 
strains were poor. One explanation was the bacteria did colonize well in mice, 
after all most strains elicited considerably high antibody responses, and the cells 
just could not be detected in aerobic environment after they had already got used 
to the anaerobic environment in vivo. This inability of the transformation between 
aerobic and anaerobic condition may be related to the fur mutation in the vaccine 
strains, as Fur involves in the regulation of this transformation (38, 92). The 
reduced expression resulted from mutations in its promoter region (changed to 
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ΔPfur81::TT araC PBAD from Pfur) might impact its regulation effect. This 
conjecture could be tested by replacing the mutated fur promoter with its 
wild-type promoter. Another possibility was the colonizing ability of the vaccine 
strains was largely reduced. Fur is a global regulator connected to virulence. It 
regulates iron metabolism and plays a role in regulation of type III secretion 
system (27, 90), which is believed to be crucial for invasion and survival in 
macrophages (17, 83, 85). Up-regulation of Fur synthesis in the vaccine strains 
may help to improve the colonizing ability of the vaccine strains. Meanwhile, 
whether the Crp-70 that worked well in lab condition can maintain its effects in 
the complicated environment in vivo needs more investigation.  
  Low growth rate is one of the characteristics of almost all araC PBAD crp-70 
strains including χ11541 and χ11695. The phenotype, which was initially 
observed in their construction repeated almost everywhere, may explain the 
performance of χ11541 and χ11695. In colonization tests, χ11695 showed lower 
colonizing ability than χ3761, χ9021 and χ11700. Slow growth usually indicates 
low efficiency in utilizing nutrients, and it may put the bacteria into a difficult 
situation in the host where nutrient supply is poorer than in vitro growth and lots 
of threats from immune system exist. Furthermore, the lower antibody response 
could be largely attributed to the slow growth. Anti-LPS IgG is an indicator of the 
in vivo growth of the vaccine strains. The anti-LPS response of χ11541(pYA4088) 
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was 100 times lower than that of others, reflecting its weak growth within the host, 
and illustrating its anti-PspA IgG, which was also 100 times lower than that of 
other strains. The reason for this slowness is not clear. Checking the pH during in 
vitro culture and microscopic morphology may provide some clues to clarify this 
problem. Crp-70 enables the bacteria to use multiple sugars at the same time. This 
property may accelerate the acidification and impact bacterial growth. 
Morphological changes such as conversion from smooth colonies (virulent) to 
rough colonies (avirulent) may undermine the in vivo growth and colonization. 
More information can be obtained by microarray analysis on the global effects by 
Crp and Crp*. Besides, the araC PBAD region in the suicide vector pYA4764 
should be sequenced and compared with other araC PBAD, in order to check if 
there are any unexpected mutations reducing the transcription efficiency.  
  The χ11443(pYA3493) showed unusually high level of anti-PspA IgG, which 
was over 1:1000 in week 6. Actually, the uncommon deviation mainly came from 
two individuals in this group. Those two mice were the ones with the strongest 
responses in weeks 4, 6 and 8, and their titers in week 6 were over 1:10000. t-test 
showed the data obtained from them in those three weeks did not fit the normal 
distribution and thus could be excluded from this group.  
  The correlation between immunogenicity and protection of the vaccine strains 
was analyzed, and no significant correlation was detected. It was consistent with 
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previous researches (75), since cellular immunity especially CD4+ T-cell 
responses was also required for protection against pneumococcal challenges (61). 
However, there were studies reporting such correlation was observed in some of 
the previous researches (30, 101, 102). In general, whether there is a correlation 
between antibody titer and protection is still controversial. 
  In conclusion, I constructed two regulated delayed attenuated Salmonella 
vaccine strains harboring a cAMP-independent crp, crp-70, and demonstrated 
their effects in activating genes subject to catabolite repression. Then I 
investigated the colonization, immunogenicity and protection of different 
combinations of promoters and crp alleles. The Pcrp promoted strains, χ3761 (Pcrp 
crp) and χ11700 (crp-70) showed better colonizing ability. All vaccine strains but 
the χ11541 (araC PBAD crp-70) elicited good IgG responses against PspA and LPS, 
but their capacity of invasion and colonization still needs improvement. During 
relevant challenge, χ11464(pYA4088) (araC PBAD crp) provided the best 
protection, followed by χ11443(pYA4088) (Pcrp crp).  
With respect to the crp-70 strains, especially the araC PBAD crp-70 strains, they 
did not show expected advantages over the wild-type crp strains. araC PBAD 
crp-70 led to slow growth. If the growth efficiency can be enhanced, χ11541 
(araC PBAD crp-70) still has the potential to become a vaccine candidate. The 
performance of crp-70 was better than araC PBAD crp-70. Its single-mutated strain 
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exhibited similar colonizing ability to the wild-type strain, and its vaccine strain 
showed promising immunogenicity. These two strains showed some protection, 
but it was slightly lower than the other two strains.   
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